Cytovance Biologics And PolyPeptide Announce Collaboration For Microbial And Mammalian-Expressed Peptide Drugs

This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of product requirements.

In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide’s capabilities in complex peptide development and manufacturing.

Axel Schleyer, CCO of Cytovance Biologics: “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand.”

Trishul Shah, PolyPeptide Director of Business Development: “With a track record of over 1,000 therapeutic peptides manufactured, PolyPeptide offers deep peptide development and synthesis capabilities. The collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.”

The two companies have partnered before on specific customer projects. The new collaboration broadens the partnership to the benefit of drug developers looking for additional capacity, fast ramp-up, and increased efficiency, helping to propel new peptide products to the clinic and the market.

About Cytovance Biologics:
Cytovance Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) offering ingenuity and integrated development services to support large molecule biologics throughout the journey from R&D to regulatory approval. These services include mammalian cell line development, cell banking, microbial strain development, process and analytical development, process characterization, and cGMP manufacturing. The company's 140,000+ sq. ft. state-ofthe-art facilities in America’s Heartland are designed to meet US, EU, and global regulatory requirements. For more information, visit https://cytovance.com/

About PolyPeptide:
PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, visit polypeptide.com.